Ebglyss ^*

Ebglyss (generic name: lebrikizumab) is a self-injectable medicine that treats adults and adolescents 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that has not been adequately controlled with other topical therapies or who cannot tolerate them. Lebrikizumab can only be prescribed for patients who weigh at least 40 kg. Atopic dermatitis is a chronic disease that causes inflammation, redness, and skin irritation. It is a common condition that usually starts in childhood, but people can get the disease at any age. Atopic dermatitis is not contagious. Ebglyss can be used with or without topical corticosteroids.

Dosage

Ebglyss must be used exactly as prescribed. It is administered by subcutaneous injection in a single-use prefilled pen or syringe with a needle shield. An adult or caregiver should administer the injection for children. Read the instructions that come with the pack before use.

Storage

Ebglyss is delivered in a cooler pack and must be stored in the refrigerator. It must not be frozen or used if it has accidentally frozen.

Common questions about Ebglyss

What is the main cause of atopic eczema?

Researchers now believe that defective genes that control a specific protein that helps the body maintain a healthy layer of skin may be the root cause of atopic dermatitis (eczema). When this protein is missing, skin barriers change, allowing moisture to escape and exposing the immune system to irritants.

What is the difference between eczema and atopic eczema?

Atopic dermatitis (AD) is an inflammatory skin condition and the most common type of eczema. AD is often associated with other atopic conditions, including hay fever and asthma.